Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-4050 Rollover Study in Alström Syndrome
NCT03184584Phase 3Terminated
- Sponsor
- Liminal BioSciences Inc.
- Start
- Oct 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fezagepras in Alström syndrome (ALMS), sponsored by Liminal BioSciences Inc.. Started Oct 2017; status: terminated.
02
Drugs
fezagepras
03
Conditions
Alström syndrome (ALMS)
Beyond the preview
Go deeper on NCT03184584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03184584.